↓ Skip to main content

Hereditary Tyrosinemia

Overview of attention for book
Cover of 'Hereditary Tyrosinemia'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Discovery of Hereditary Tyrosinemia in Saguenay- Lac St-Jean
  3. Altmetric Badge
    Chapter 2 Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1
  4. Altmetric Badge
    Chapter 3 Molecular Aspects of the FAH Mutations Involved in HT1 Disease
  5. Altmetric Badge
    Chapter 4 Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1
  6. Altmetric Badge
    Chapter 5 Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine
  7. Altmetric Badge
    Chapter 6 The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec
  8. Altmetric Badge
    Chapter 7 Liver Transplantation for Hereditary Tyrosinaemia Type 1 in the United Kingdom
  9. Altmetric Badge
    Chapter 8 NTBC and Correction of Renal Dysfunction
  10. Altmetric Badge
    Chapter 9 Liver Cancer in Tyrosinemia Type 1
  11. Altmetric Badge
    Chapter 10 Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
  12. Altmetric Badge
    Chapter 11 Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening
  13. Altmetric Badge
    Chapter 12 Tyrosinemia Type I in Japan: A Report of Five Cases
  14. Altmetric Badge
    Chapter 13 Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update
  15. Altmetric Badge
    Chapter 14 Hepatorenal Tyrosinemia in Mexico: A Call to Action
  16. Altmetric Badge
    Chapter 15 Hereditary Tyrosinemia Type 1 in Turkey
  17. Altmetric Badge
    Chapter 16 From Weed Killer to Wonder Drug
  18. Altmetric Badge
    Chapter 17 The Québec NTBC Study
  19. Altmetric Badge
    Chapter 18 Dietary Considerations in Tyrosinemia Type I
  20. Altmetric Badge
    Chapter 19 Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
  21. Altmetric Badge
    Chapter 20 Fah Knockout Animals as Models for Therapeutic Liver Repopulation
  22. Altmetric Badge
    Chapter 21 Gene Therapy in Tyrosinemia: Potential and Pitfalls
Attention for Chapter 11: Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening
Altmetric Badge

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening
Chapter number 11
Book title
Hereditary Tyrosinemia
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-3-319-55780-9_11
Pubmed ID
Book ISBNs
978-3-31-955779-3, 978-3-31-955780-9
Authors

Anibh M. Das, Sebene Mayorandan, Nils Janzen

Abstract

Hepatorenal tyrosinaemia (HT1) is a serious condition that used to be fatal before the advent of nitisinone (NTBC, Orfadine®) as a therapeutic option. We have recently shown that selective screening is inadequate as initial symptoms are often uncharacteristic which leads to a considerable delay in diagnosis and treatment. This has a negative impact on morbidity and mortality as well as long-term outcome. For example, the odds ratio to develop hepatocellular carcinoma is 12.7 when treatment is initiated after the first birthday compared to start of treatment in the neonatal period. Timely diagnosis is only possible when neonatal mass screening is operational. HT1 meets all the criteria for neonatal mass screening at a clinical and analytical level. The natural course of the disease is well known, clinically there is a latent phase in most patients when presymptomatic treatment can be initiated. There are no mild phenotypes which do not require treatment. Using succinylacetone as the screening parameter a highly specific and sensitive test is available with acceptable financial burden. Neonatal mass screening for HT1 is acceptable to the target population as it can be performed simultaneously with the already existing screening tests in dried blood, there are no false negative and false positive cases and the financial burden to the health system is moderate. An efficient treatment is available with nitisinone and protein-reduced diet supplemented with special amino acid mixtures. Despite compelling evidence in favour of a neonatal mass screening for HT1 only 57% of European centres taking part in our recent cross-sectional study have included HT1 in their newborn screening programme.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 25%
Other 2 25%
Researcher 1 13%
Professor > Associate Professor 1 13%
Unknown 2 25%
Readers by discipline Count As %
Medicine and Dentistry 3 38%
Agricultural and Biological Sciences 1 13%
Business, Management and Accounting 1 13%
Unknown 3 38%